Get the Daily Brief
Latest Biotech News
AAV-mediated CCR5 blockade for long-term SHIV suppression
Researchers at Oregon Health & Science University reported that AAV gene therapy expressing a CCR5-blocking antibody can drive long-term viral suppression in SHIV-infected macaques. The approach...
IPO and financing momentum in respiratory and oncology biotech
Two IPO-related items highlighted fresh capital access for drug developers targeting respiratory disease and oncology commercialization. Avalyn Pharma priced a $300 million IPO to fund late-stage...
New FDA leadership for biologics regulation
Katherine Szarama was named acting director of the FDA’s Center for Biologics Evaluation and Research (CBER), overseeing regulation for vaccines, gene therapies, and the blood supply. The...
Securing FDA pathway momentum for gene therapy in Huntington’s disease
UniQure said it plans to seek UK approval for AMT-130, its Huntington’s gene therapy, after a positive meeting with UK regulators. The company plans a marketing application later this year and...
Regulatory restraint and trial-level concern: Tavneos withdrawn in response to trial integrity findings
The FDA’s actions involving ChemoCentryx’s avacopan (Tavneos) came under renewed focus after an investigation prompted steps toward withdrawal from the U.S. market. The allegation centered on new...
Clinical signal in oncology diagnostics and companion testing
Guardant Health and Nuvalent agreed to collaborate on oncology companion diagnostics across multiple clinical studies. Guardant will supply tissue and liquid biopsy tools to support Nuvalent’s...
Biotech deal activity: Leo Pharma enters gene therapy with Replay acquisition
Leo Pharma agreed to acquire Replay Holdings for $50 million, marking its entry into gene therapy through Replay’s high-capacity herpes simplex virus (HSV) vectors. The seed-stage portfolio is...
Diagnostics platform approval: GeneMind’s SURFSeq 5000 Dx registered with NMPA
GeneMind Biosciences reported that China’s NMPA registered its SURFSeq 5000 Dx high-throughput sequencer as a Category III medical device. The registration enables clinical deployment in China for...
Regulatory and FDA leadership shifts
The FDA moved to change leadership of its biologics oversight structure, naming Katherine Szarama as acting director of the Center for Biologics Evaluation and Research (CBER), which regulates...
Oncology FDA advisory outcomes and label-risk dynamics
Two separate FDA advisory panel threads highlighted how evidence standards for oncology use cases are tightening. An ODAC discussion of AstraZeneca’s oral SERD camizestrant produced a near-split...
Biotech funding via IPOs
Two IPO debuts underscored strong investor appetite for late-stage-ready and category-defining specialties. Seaport Therapeutics and Hemab Therapeutics entered public markets through a combined...
M&A and rare disease platform expansion
Chiesi Group agreed to acquire KalVista Pharmaceuticals in a $1.9 billion deal, extending its rare disease footprint with Ekterly (sebetralstat), a plasma kallikrein inhibitor for hereditary...
Cell therapy and immune engineering—clinical signals
Stem cell memory-enriched CAR T data moved into the spotlight as a first-in-human program reported complete remissions at low doses without chemotherapy preconditioning. The approach uses stem...
Gene therapy and vector development—regulatory and preclinical progress
UniQure advanced its regulatory recovery path for Huntington’s disease, planning a UK marketing application for AMT-130 after a positive meeting with UK regulators. The decision is backed by...
Clinical trial failure or regulatory risk in oncology
Bristol Myers Squibb’s Krazati (fruquintinib) moved into approval-risk territory after failing a confirmatory Phase 3 study in second-line colorectal cancer. The company spokesperson confirmed to...
New clinical evidence for GLP-1 outside classic metabolic targets
Semaglutide moved beyond standard obesity and diabetes endpoints as a small clinical trial reported lower heavy drinking days among individuals with alcohol use disorder and obesity. Investigators...
Microbiome and immunology drug discovery signals
Microbiome-derived therapy advanced as researchers reported Bifidobacterium-derived nanoparticles that combat alcoholic liver disease via mechanisms linked to biophysical and inflammatory...
Cell and gene engineering platforms—scalable genome editing and synthesis
Biohub moved to scale “virtual cell” tooling with a major $500 million commitment to build AI-based predictive cell models, aiming to generate multimodal datasets and open access resources. The...
Regulatory action / rare disease drug integrity
The FDA moved to withdraw Tavneos (avacopan) from the US market after investigators found serious data-integrity issues in the pivotal trial that supported approval. The drug, developed by...
Oncology FDA advisory committee stance on ctDNA-guided switching
FDA oncology advisors again pushed back on AstraZeneca’s ctDNA-driven switching strategy for camizestrant. Two separate ODAC-focused writeups (one noting a related “new paradigm” framing and one...